Leerink Partners Remains Bullish on Amicus Therapeutics (FOLD) Following Announced Scioderm Acquisition

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE

Amicus Therapeutics to Acquire Rare Disease Company Scioderm, Inc.

August 31, 2015 6:00 AM EDT

Scioderm's Lead Drug Candidate Zorblisa in Phase 3 Study for Rare Disease Epidermolysis Bullosa (EB) Granted FDA Breakthrough Therapy Designation

FDA Has Agreed to Rolling NDA Submission for Zorblisa Beginning in 4Q15

Acquisition Advances Amicus Vision to Create One of the World's Leading Rare Disease Biotechnology Companies

Conference Call Today at... More